Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-centre Phase 2 Study of Vinorelbine Plus 3-weekly Trastuzumab in Metastatic Breast Cancer Overexpressing Her-2

NCT00401427 is registered in ClinicalTrials.gov with National Cancer Institute, Naples as lead sponsor.

NCT NCT00401427
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00401427 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-centre Phase 2 Study of Vinorelbine Plus 3-weekly Trastuzumab in Metastatic Breast Cancer Overexpressing Her-2
Lead sponsor
National Cancer Institute, Naples
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2002
Completion date
December 31, 2006
Enrollment
50
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer